Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Data Meets Decision: Expert Approaches to Perioperative Immunotherapy in LA HNSCC
Data Meets Decision: Expert Approaches to Perioperative Immunotherapy in LA HNSCC
CME/CE Virtual Event
Data Meets Decision: Expert Approaches to Perioperative Immunotherapy in LA HNSCC
September 15, 2026
06:00 PM - 06:45 PM CEST
0.75 credits
NEW EPISODE
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
MinuteCE®
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
NEW EPISODE
The Power of Timing: Therapies That Change Outcomes
The Power of Timing: Therapies That Change Outcomes
MinuteCE®
The Power of Timing: Therapies That Change Outcomes
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
Overcoming Clinical Inertia to Individualize Myelofibrosis Treatment
Overcoming Clinical Inertia to Individualize Myelofibrosis Treatment
Project Oncology®
Overcoming Clinical Inertia to Individualize Myelofibrosis Treatment
Alexandria May, PharmD, BCPS; Prithviraj Bose, MD
- Alexandria May, PharmD, BCPS
- Prithviraj Bose, MD
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
MinuteCE®
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Tiffany Traina, MD, FASCO; Javier Cortes, MD, PhD
0.75 program credits
- Tiffany Traina, MD, FASCO
- Javier Cortes, MD, PhD
0.75 program credits
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
MinuteCE®
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
Tiffany Traina, MD, FASCO
0.75 program credits
- Tiffany Traina, MD, FASCO
0.75 program credits
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
MinuteCE®
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO; Javier Cortes, MD, PhD
0.75 program credits
- Tiffany Traina, MD, FASCO
- Javier Cortes, MD, PhD
0.75 program credits
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
MinuteCE®
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
Javier Cortes, MD, PhD
0.75 program credits
- Javier Cortes, MD, PhD
0.75 program credits

Medical News

Medical News
Perioperative Systemic Therapy vs Surgery Alone in Colorectal Peritoneal Metastases
07/21/2026
Read more
Medical News
Talquetamab And Teclistamab Show Early Signal In Myeloma
07/20/2026
Read more
Medical News
MRI Radiomics Score And ADC Improve HCC Recurrence Prediction
07/20/2026
Read more
Medical News
ARCHER Trial Explores Vaccine Strategy to Prevent ALK Inhibitor Resistance in Advanced NSCLC
07/17/2026
Read more

CME/CE

MinuteCE®
Redefining First-Line Therapy of Metastatic TNBC: Integrating TROP2-Directed ADCs Into Modern Treatment Strategy
Tiffany Traina, MD, FASCO; Javier Cortes, MD, PhD
0.75 credits 6 episodes
- Tiffany Traina, MD, FASCO
- Javier Cortes, MD, PhD
0.75 credits 6 episodes
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
MinuteCE®
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
Javier Cortes, MD, PhD
0.75 program credits
- Javier Cortes, MD, PhD
0.75 program credits
What’s Next for TROP2-Directed ADCs in TNBC?
What’s Next for TROP2-Directed ADCs in TNBC?
MinuteCE®
What’s Next for TROP2-Directed ADCs in TNBC?
Tiffany Traina, MD, FASCO
0.75 program credits
- Tiffany Traina, MD, FASCO
0.75 program credits
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
CME/CE Virtual Event
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
September 24, 2026
03:30 PM - 04:30 PM ET
1.00 credit

Clinical Practice

NEW EPISODE
Precision in Practice—Bringing Targeted Therapy to mHSPC
Precision in Practice—Bringing Targeted Therapy to mHSPC
MinuteCE®
Precision in Practice—Bringing Targeted Therapy to mHSPC
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
Personalizing Long-Term mCSPC Treatment Decisions
Personalizing Long-Term mCSPC Treatment Decisions
Project Oncology®
Personalizing Long-Term mCSPC Treatment Decisions
Charles Turck, PharmD, BCPS, BCCCP; Bilal Siddiqui, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Bilal Siddiqui, MD
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
CME/CE Virtual Event
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
August 20, 2026
02:30 PM - 03:30 PM ET
1.00 credit
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
CME/CE Virtual Event
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
September 03, 2026
02:00 PM - 03:00 PM ET
1.00 credit

Programs

NEW EPISODE
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
MinuteCE®
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
CME/CE In-Person & Virtual Event
Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
September 11, 2026
Houston, Texas
1.00 credit
Interpreting and Applying cGVHD Clinical Trial Data
Interpreting and Applying cGVHD Clinical Trial Data
Project Oncology®
Interpreting and Applying cGVHD Clinical Trial Data
Charles Turck, PharmD, BCPS, BCCCP; Christopher Graham, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Christopher Graham, MD
The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
CME/CE
The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
Neeraj Agarwal, MD, FASCO; Rana McKay, MD
0.25 credits
- Neeraj Agarwal, MD, FASCO
- Rana McKay, MD
0.25 credits